Abattis Bioceuticals Corp.
ATTBF
$0.00
$0.000.00%
| 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | 09/30/2018 | |
|---|---|---|---|---|---|
| Revenue | 8,915.79% | 47,650.00% | -64.44% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8,915.79% | 47,650.00% | -64.44% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 6,363.16% | 28,450.00% | -46.67% | -- | -- |
| SG&A Expenses | 109.45% | -84.11% | -90.99% | -75.42% | -467.92% |
| Depreciation & Amortization | 102.41% | -98.93% | 87.06% | 159.32% | -7,193.66% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 108.60% | -87.51% | -90.82% | -75.23% | -572.63% |
| Operating Income | -105.89% | 89.30% | 90.83% | 75.24% | 572.77% |
| Income Before Tax | 98.29% | 89.84% | 98.84% | 76.85% | -1,431.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 98.30% | 89.77% | 98.84% | 76.85% | -1,431.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 105.20% | -- | -- | -- | -262.05% |
| Net Income | 98.34% | 89.77% | 98.84% | 76.85% | -1,188.67% |
| EBIT | -105.89% | 89.30% | 90.83% | 75.24% | 572.77% |
| EBITDA | -105.77% | 85.60% | 91.00% | 75.52% | 578.49% |
| EPS Basic | 98.58% | 91.37% | 99.35% | 90.54% | -397.47% |
| Normalized Basic EPS | 100.34% | 91.95% | 94.48% | 89.70% | -910.34% |
| EPS Diluted | 98.58% | 91.37% | 99.35% | 90.54% | -397.47% |
| Normalized Diluted EPS | 100.34% | 91.95% | 94.48% | 89.70% | -910.34% |
| Average Basic Shares Outstanding | 13.52% | 23.32% | 60.14% | 142.49% | 183.15% |
| Average Diluted Shares Outstanding | 13.52% | 23.32% | 60.14% | 142.49% | 183.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
